Teva Israel LTD, Israel

Calcineurin Inhibitors, Immunosuppressant. Tacrolimus 0.5, 1, 3, 5 mg.
PR Caps.50 X0.5/1/3/5 mg
For kidney transpl.: Once dly in the morn., on empty stomach, 0.20 - 0.30 mg/kg within 24 h from surg. complet. Dose to be adjust. as per clinic. assess. For liver transpl.: Once dly in the morn., on empty stomach, 0.10 - 0.20 mg/kg within 12-18 h from surg. complet. Dose to be adjust. as per clinic. assess.
Prophylaxis of transpl. reject. in adult kidney or liver allograft recipts.. Tmt. of allograft reject. resist. to tmt. with other immunosuppress. in adult kidney or liver allograft recip. ptts.
C/I:  Hypersens. incl. other macrolides.

TCA. Amitriptyline 10 mg.
FC tab.X 28
Major depress. disord.  Tmt. should be init. at low level and incr. grad., noting carefully clinic. resp. and evidence of intolerab. Adlts.: init. 25 mg 2 times/d (50 mg/d). If necessary, can be incr. by 25 mg every other d. up to 150 mg/d div.in 2 doses.
Nocturnal enuresis ped. pop.
• childr. aged 6 to 10: 10 mg – 20 mg/d. A suitable dosage form should be used for this age group.
• childr. aged 11 and above: 25 mg – 50 mg/d. Dose should be incr. grad. To be admin. 1-1½ hours before bedtime.
Relief of symptoms of depress. Endogenous depress. is more likely to be
alleviated than other depress. states.
Enuresis nocturna
C/I: Recent MI. Any degree of heart block or disord. of cardiac rhythm and coron. artery insuff./ Concom. tmt. with MAOIs. Tmt. with amitriptyline may start 14 days after discont. of irrevers. non- select. MAOIs and min. one d. after discont. of the revers. moclobemide. Tmt. with MAOIs may be introd. 14 days after discont. of amitriptyline/Sev. liver dis./Childr. under 12 years of age.

Tyrosine Kinase Inhibitor, VEGF Inhibitor. Axitinib 1 mg, 5 mg.
FC. TAB 60 X  1/5 mg
Recomm. starting dose is 5 mg twice/d. Administer doses approx. 12 hs apart. Dose incr. or reduct. is based on indiv. safety and tolerab. See full prescript. data
Tmt. of adv.renal cell carcinoma (RCC) after failure of one prior syst. ther.
C/I: Hypersens.

5-α Reductase Inhibitor. Dutasteride 0.5 mg.
SOFT CAPS.: 10, 30×0.5mg. 1 cap. (0.5 mg) once a day.
Tmt. of moder. –sev. sympt. of BPH.
Reduct. in the risk of acute urinary retent.(AUR) and surg. in pts. with moder.- sev. sympt. of BPH.
C/I: women, child. and adolesc. – hypersens. incl. to other 5-alpha reductase inhib., pts with sev. hepatic impairm.

Anti-Androgen. Enzalutamide 40 mg.
FC caps 120 X 40 mg
160 mg enzalutamide (4 caps.) as a sgle daily dose.
tmt of adult men with high-risk non-metast. castration resist. prostate cancer (CRPC). – tmt. of adult men with metast. CRPC who are asymptom. or mildly symptom. after failure of androgen deprivation ther. in whom chemother. is not yet clinically indicated.- tmt. of adult men with metast. CRPC whose dis. has progressed on or after docetaxel ther. - tmt of adult men with metast. hormone-sensitive prostate cancer (mHSPC) in combin. with androgen deprivation ther.
As monother. or in combin. with androgen deprivation ther. for the tmt of adult men with high risk biochemical recurrent (BCR) non-metast. hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiother.
C/I: hypersens. Women who are or may become pregn.

Potassium Channel Blocker. Fampridine 10 mg.
PR Tabs 28/56 X 10 mg
One 10 mg tab, twice daily, taken 12 hours apart .
Improvem. of walking in adlt. pts. with MS with walking disab. (EDSS 4-7)
C/I:  Hypersens. Conc. tmt. with other med. prod. contain. fampridine (4-aminopyridine). Pts. with  hist.or current seizures. Pts. with mild, mod. or sev. renal impairm. (creat. clear. <80 ml/min).
Concom. use with inhibit. of Organic Cation
Transporter 2 (OCT2) for ex., cimetidine.